This radiopharmaceutical with a half-life of 6.7 days, reduces the pain caused by bone metastases from cancers such as breast and prostate through emitting beta particles. Moreover, due to being a gamma emitter, it can be used for imaging and the treatment follow-up purposes, too.
Radiopharmaceutical
theragnostic
